A5070028463- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Botulinum Toxin and Related Neurological Disorders
- EEG and Brain-Computer Interfaces
- Dementia and Cognitive Impairment Research
- Functional Brain Connectivity Studies
- Genetic Neurodegenerative Diseases
- Transcranial Magnetic Stimulation Studies
- Neural and Behavioral Psychology Studies
- Alzheimer's disease research and treatments
- Advanced Neuroimaging Techniques and Applications
- Restless Legs Syndrome Research
- Neurological Disease Mechanisms and Treatments
- Attention Deficit Hyperactivity Disorder
- Advanced MRI Techniques and Applications
- Vagus Nerve Stimulation Research
- Diet and metabolism studies
- Autism Spectrum Disorder Research
- Neurobiology of Language and Bilingualism
- Neurological and metabolic disorders
- Dysphagia Assessment and Management
- Pharmacological Effects and Toxicity Studies
- Health Systems, Economic Evaluations, Quality of Life
- Brain Tumor Detection and Classification
- Neuroscience and Neural Engineering
Ljubljana University Medical Centre
2016-2025
University of Ljubljana
2015-2024
Očesna Klinika UKC Ljubljana
2020-2024
University Medical Center
2012
Nevro (United States)
2002
University College London
1989-2001
National Hospital for Neurology and Neurosurgery
1996-2001
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
1993
University of Gothenburg
1993
Middlesex Hospital
1993
ABSTRACT Subcutaneous apomorphine infusion (Apo) and intrajejunal levodopa (IJLI) are two treatment options for patients with advanced Parkinson's disease (PD) refractory motor complications, varying cost of treatment. There no multicenter studies comparing the effects strategies. This open‐label, prospective, observational, 6‐month, study compared 43 on Apo (48.8% males, age 62.3 ± 10.6 years; duration: 14 4.4 median H & Y stage 3; interquartile range [IQR]: 3‐4) 44 IJLI (56.8% 62.7 9.1...
Abstract Objective Real‐life observational report of clinical efficacy bilateral subthalamic stimulation (STN‐DBS), apomorphine (APO), and intrajejunal levodopa infusion (IJLI) on quality life, motor, nonmotor symptoms (NMS) in Parkinson's disease (PD). Methods In this prospective, multicenter, international, real‐life cohort observation study 173 PD patients undergoing STN‐DBS (n = 101), IJLI 33), or APO 39) were followed‐up using PDQuestionnaire‐8, NMSScale (NMSS), Unified Rating Scale...
There are currently no standard diagnostic criteria for characterizing advanced Parkinson's disease (APD) in clinical practice, a critical component determining ongoing care and therapeutic strategies, including transitioning to device-aided treatment. The goal of this analysis was determine the proportion APD vs. non-advanced PD (non-APD) patients attending specialist clinics demonstrate burden APD. OBSERVE-PD, cross-sectional, international, observational study, conducted with 2615 at 128...
Abstract Botulinum toxin (BT) therapy is a complex and highly individualised defined by treatment algorithms injection schemes describing its target muscles their dosing. Various consensus guidelines have tried to standardise improve BT therapy. We wanted update by: (1) Acknowledging recent advances of algorithms. (2) Basing dosing tables on statistical analyses real-life data 1831 injections in 36 different 420 dystonia patients 1593 31 240 spasticity patients. (3) Providing more detailed...
Human gait activity recognition is an emerging field of motion analysis that can be applied in various application domains. One the most attractive applications includes monitoring disorder patients, tracking their disease progression and modification/evaluation drugs. This paper proposes a robust, wearable data acquisition system allows either classification recorded into desirable activities or identification common risk factors, thus enhancing subject's quality life. Gait information was...
Abstract Neurophysiological evidence that transcutaneous auricular vagal nerve stimulation (taVNS) affects neuronal signalling at the cortical level is sparse. We used transcranial magnetic to assess effect of taVNS on excitability intracortical GABAergic and cholinergic circuits. In this within‐subject, double‐blind study 30 healthy participants, we TMS paradigms a single session 100 Hz sham earlobe VNS (sVNS) short‐interval inhibition (SICI) curve short‐latency afferent (SAI). Control...
Summary: Forty-six patients with Parkinson's disease experiencing motor fluctuations and not optimally controlled on levodopa received as adjunct therapy a new nonergoline dopamine agonist, ropinirole, in 3-month randomized placebo-controlled trial. Ropinirole significantly reduced the duration of off periods assessed by self-scoring diary cards. There were more nonserious dopaminergic adverse events ropinirole group. More withdrew because or insufficient therapeutic effect placebo has...
The purpose of this study is to evaluate the real-world dose utilization Dysport and BOTOX for cervical dystonia blepharospasm. Six investigational sites (five countries) were identified. Investigators abstracted data patients who received before switching or Dysport. Patients identified during scheduled clinic visits selected if they met criteria, which included treatment at least 2 consecutive years (at 1 year with BOTOX, then switched maintained on another year). A total 114 in...
Dopaminergic pathway is the most disrupted in pathogenesis of Parkinson's disease. Several studies reported associations dopaminergic genes with occurrence adverse events treatment. However, none these adopted a based approach. The aim this study was to comprehensively evaluate influence selected single nucleotide polymorphisms key on motor and non-motor treatment In total, 231 disease patients were enrolled. Demographic clinical data collected. Genotyping performed for 16 from genes....
Levodopa-entacapone-carbidopa intestinal gel (LECIG) was introduced in 2018 as a device-aided therapy for advanced Parkinson's disease (PD). The ELEGANCE study (NCT05043103) is gathering real-world data on long-term efficacy, safety and patient-reported outcomes with LECIG from 13 European countries. This article reports the planned interim analysis. enrolled patients prescribed part of routine clinical care. We evaluated at V1 before starting treatment (in seven were obtained...
Abstract Introduction We aimed to determine the added value of cerebrospinal fluid (CSF) clinical and imaging tests predict progression from mild cognitive impairment (MCI) any type dementia. Methods The risk dementia was estimated using two logistic regression models based on 250 MCI participants: first included standard measures (demographic, clinical, test information) without CSF biomarkers, second with biomarkers. Results Adding improved predictive accuracy 0.11 (scale 0–1). Of all...